Journal of Medicinal Chemistry p. 604 - 608 (1989)
Update date:2022-07-30
Topics:
Thurston
Imakura
Haruna
Li
Liu
Liu
Cheng
Lee
A principal mechanism of action of the clinical antitumor drugs etoposide (1) and teniposide (2) is the inhibition of catalytic activity of type II DNA topoisomerase and concurrent enzyme-mediated production of lethal DNA strand breaks. Substitution of the glycosidic moiety of 1 or 2 by ester and ethers, as well as the esterification and etherification of α-peltatin (4) including its glucosidic ethylidene and thenylidene cyclic acetals (25 and 26), has afforded compounds of much less activity than that of 1. The in vitro cytotoxicity (KB) appears to have no correlation with the inhibitory activity of the human DNA topoisomerase II.
View Morezhuzhou zhongle chemical co. ltd.
Contact:+86-0731 28228409
Address:Zhuzhou, Hunan, China
Shijiazhuang Haotian Chemical Co., Ltd.
Contact:86-311-85044374
Address:293 Donggang Road
Suzhou Credit International Trading Co., Ltd
Contact:+86-512-65398039
Address:Qingdeng, Hightech. District, Suzhou
Suzhou Credit International Trading Co., Ltd
Contact:+86-512-65398039
Address:Qingdeng, Hightech. District, Suzhou
Beijing ZhongDaXinHe Chemical Product Co.,Ltd(expird)
Contact:010-52876516
Address:tongzhoubeiyuan
Doi:10.1021/jo01091a039
(1959)Doi:10.1021/ja01564a058
(1957)Doi:10.1007/BF03251529
(1956)Doi:10.1039/c39950001139
(1995)Doi:10.1016/j.bmc.2008.01.018
(2008)Doi:10.1021/ol301916t
(2012)